Gene variants associated with increased risk of bone fractures, low bone mineral density

Results from a large study indicate that variants of the gene LRP5 are associated with a significant increase in the risk of fractures, by up to 20 percent, and lower levels of bone mineral density in the spine and hip, according to a study in the March 19 issue of JAMA, a theme issue on Genetics and Genomics.

Joyce B. J. van Meurs, Ph.D., of Erasmus MC, Rotterdam, the Netherlands, presented the findings of the study at a JAMA media briefing at the National Press Club in Washington, D.C.

Osteoporosis is characterized by low bone mineral density (BMD), deterioration of bone and increased risk for fractures. Studies have shown that genetic factors determine up to 80 percent of the variance in BMD, which is a major predictor of osteoporotic fractures, according to background information in the article. While the genes that contribute to differences in risk for osteoporosis and osteoporotic fractures are for the most part unknown, it is thought that the risk of developing osteoporosis is dependent on several common gene variants. Variations of the gene LRP5 have been linked to bone mass accrual and susceptibility to osteoporosis, and some reports have suggested that some of these variants contribute to change in BMD in the general population, but results have been inconclusive, partly because of small sample size.

Dr. van Meurs and colleagues examined the association between variants to the genes LRP5 and LRP6 to BMD and risk of fracture using large-scale evidence, with the combined analysis of individual-level data of the full Genetic Markers for Osteoporosis (GENOMOS) consortium, including data from 37,534 individuals from 18 participating teams in Europe and North America. Bone mineral density was assessed by dual-energy x-ray absorptiometry (an imaging technique). Fractures were identified via questionnaire, medical records, or radiographic documentation; new fracture data were available for some groups, determined via routine surveillance methods, including radiographic examination for vertebral fractures.

“In this large-scale multicenter collaborative study, we obtained evidence that genetic variation of the LRP5 gene is associated with both BMD and fracture risk. The magnitude of the effects was modest but very consistent across studies,” the authors write. “Based on the general acceptance that a 1-standard deviation reduction in bone mass doubles the fracture rate, an increase of fracture risk of about 15 percent to 20 percent is expected. This is similar to the observed effects on fracture, although adjustment for BMD only partly reduced the increase in fracture risk. This could raise the possibility of effects on bone quality, bone dimension, or other nonskeletal determinants of fracture, but also could be due to error in measurement of BMD. Further work will be required to address this point.”

“Our findings demonstrate that the modest effects of common genetic variations in complex diseases can be effectively addressed through large consortia and coordinated, standardized analysis. Such effects might be missed by smaller and potentially underpowered individual studies. This prospective collaborative study with individual level-data of 37,534 participants shows an effect of LRP5 genetic variation on both BMD and risk of fracture. While some other common variants have been associated previously with osteoporosis phenotypes [physical manifestations] with large-scale evidence, this may be the first time that an association in this field crosses the threshold of genome-wide statistical significance.”

“Although the magnitude of the effect was modest, the effect was very consistent in different populations and independent of sex or age. This suggests a role for LRP5 in determining BMD and fracture risk throughout life in the general population. Although any single marker explains only a small portion of the phenotype risk, identification of several such osteoporosis risk variants may eventually help in improving clinical prediction. Single genetic risk variants such as LRP5 may also offer useful insights about mechanisms and pathways that may be useful in drug development,” the researchers conclude.

Source: JAMA and Archives Journals

Related stories:

Genotyping takes us closer to an osteoporosis fingerprint
For the first time ever, an extensive genome-wide search has been undertaken to find the genes linked to osteoporosis and fracture. Five regions of interest have been identified that appear to warrant further scientific investigation.
Osteoporosis drug fosamax linked to heart problem
Women who have used Fosamax are nearly twice as likely to develop the most common kind of chronically irregular heartbeat (atrial fibrillation) than are those who have never used it, according to research from Group Health and the University of Washington published in the April 28 Archives of Internal Medicine.
Study: Impact Exercise Increases Bone Mass, Decreases Fracture Risk
Two new studies conducted by Oregon State University researchers show that jumping exercises conducted over a single school year during early childhood resulted in significant bone mass increases ranging between 3 percent and 8 percent.
Diuretics associated with bone loss in older men
Older men who take loop diuretics, commonly prescribed drugs for heart failure and hypertension, appear to have increased rates of hip bone loss than men who are not taking this medication, according to a report in the April 14 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
Make or break time for osteoporosis treatment
Women who do not comply with treatment instructions for osteoporosis or who do not respond to treatment are more likely to suffer further fractures, which seriously affects their quality of life.
Launch of Web-based tool to predict risk of bone fracture
It will soon be possible for anyone over 60 to predict their individual risk of bone fracture with the aid of a simple web-based tool, developed by the Sydney-based Garvan Institute of Medical Research.
Cancer risk slightly higher for women in discontinued hormone treatment trial
A follow up study of participants in the Women’s Health Initiative (WHI) clinical trial led by a University of North Carolina at Chapel Hill researcher has found that women who were taking the combined hormone therapy of estrogen plus progestin may have an increased risk of cancer since the intervention was stopped, compared to participants in the trial’s placebo group.
Simple solutions the best for pain in the neck
It might just be that the most effective solutions to a pain in the neck are the simplest. According to a University of Alberta-led task force assigned the job of finding the best way to take the sting out of neck pain, the often debilitating ailment's best treatment is still more closely associated with a loving spouse's neck rub than anything the advancements of modern medicine have to offer.

News discussion:

Medicine & Health news